NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5049
-0.0251 (-4.74%)
As of 3:53PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.5300
Open0.5000
Bid0.4900 x 1200
Ask0.4909 x 1800
Day's Range0.4760 - 0.5300
52 Week Range0.3700 - 5.0000
Volume6,722,206
Avg. Volume3,029,301
Market Cap36.059M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-2.5490
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • Benzinga3 hours ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • PR Newswireyesterday

    New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

    VANCOUVER, May 23, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that new data for its Tiara™ ("Tiara") transcatheter mitral valve replacement device and Neovasc Reducer™ ("Reducer") device for the treatment of refractory angina were presented in several presentations at the EuroPCR 2019 Conference held this week in Paris, France.

  • Benzingayesterday

    The Daily Biotech Pulse: Breakthrough Therapy Designation For Iovance, Guardant Prices Offering, 2 Stocks to Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Axsome Therapeutics Inc (NASDAQ: AXSM ) Milestone Pharmaceuticals ...

  • PR Newswire2 days ago

    Neovasc Announces Positive Two-Year Follow-up Safety and Efficacy Data for the Neovasc Reducer™ in a Peer Reviewed Article in the International Journal of Cardiology

    VANCOUVER, May 22, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology has published a peer reviewed article regarding long term sustained efficacy and safety of the Reducer therapy in 50 patients suffering from refractory disabling angina. "This study shows us that the Reducer has a sustained therapeutic effect at two years across a large patient population. In addition, we believe this study provides valuable long-term safety data that further supports cardiologists use of the Reducer as a therapeutic option for patients suffering from refractory angina," commented Prof. Shmuel Banai, Medical Director of Neovasc.

  • PR Newswire8 days ago

    Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN) announced today that it has closed its previously announced private placement (the "Private Placement") of (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company (the "Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering"). The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Capital Market.

  • PR Newswire10 days ago

    Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to Strul Medical Group LLC ("SMG") (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company ("Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering").

  • Associated Press15 days ago

    Neovasc: 1Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, came to 20 cents per share. The medical device company posted revenue ...

  • CNW Group15 days ago

    /C O R R E C T I O N from Source -- Neovasc Inc./

    The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. While the Company is always considering ways to improve its capital position on terms that the Company believes are favorable, there can be no assurance that any financing will be completed.

  • PR Newswire18 days ago

    Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

    This is especially true when these people suffer from refractory angina, which is angina that persists despite optimal drug therapy and revascularization. "We are pleased to have treated the 1,000th patient to receive the Reducer therapy at the Inselspital Universitätsspital Bern". The Reducer therapy now totals medical evidence spanning 1,000 patients and 14 years of follow up.

  • PR Newswire21 days ago

    Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

    Conference Call Scheduled for 4:30 pm Eastern Time on May 9 th   NASDAQ, TSX: NVCN VANCOUVER , May 3, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: ...

  • PR Newswire28 days ago

    Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

    VANCOUVER, April 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided highlights from the  85th Annual Conference of the German Society of Cardiology ("DGK"), which is taking place in Mannheim, Germany, April 24 – 27, 2019. Prof. Gori (Mainz) and Prof. Reinecke (Münster) chaired a symposium on the Reducer, which included presentations from several physicians, incl.

  • CNW Grouplast month

    Neovasc Announces Resolution of Last Remaining Active Litigation

    VANCOUVER , April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court"). Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .

  • PR Newswirelast month

    Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

    VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology (the "IJC") has published a peer reviewed article demonstrating that coronary sinus ("CS") narrowing through the use of the Neovasc Reducer™ (the "Reducer") improves diastolic function and relaxation of the heart. "We are pleased to report evidence that CS narrowing may also improve diastolic function in patients with chronic refractory angina and proven myocardial ischemia.

  • Associated Press2 months ago

    Neovasc: 4Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...

  • PR Newswire2 months ago

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

    NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment ...